With the help of double guidance and double check， DSA + MDCT imaging technology can clearly display the location of tumor and its surrounding as well as the changes of lesion after treatment. It can also easily detect recurrence and metastasis， calculate how much the lesion shrinks， and reduces damage during precise intervention. At the same time， it creates condition for patients to undergo radical surgery， extending their survival time and increasing the survival rate.
DSA + CT imaging technology not only display the size， location， density and margin of tumor， but also spot the location of tumor and its surrounding as well as the changes of lesion after treatment. It can also easily detect recurrence and metastasis and calculate how much the lesion shrinks. Therefore， it has been the first choice for the examination before and after treatment.
Advantages：
1. Precise intervention
Through DSA＋CT technology， two 2D images combines to form a 3D image which provides the panorama of blood supply of lesion to make sure effective treatment on the targeted lesion.
2. Universal coverage
DSA+CT can monitor the blood supply of the lesion through multiple angles， so that each lesion and each part of the lesion can be effectively treated， and images can be verified immediately after the operation， providing support for endovascular treatment， improving work efficiency and reducing exposure time.
3. Less damage
Compared with other examinations， DSA+CT can more clearly show the relationship between the tumor and other surrounding tissues， so as to ensure effective treatment of the targeted lesion but no damage to the surrounding normal organs， thus ensuring the safety of interventional therapy and minimizing complications.
Indications：
1. For confirmed malignant tumors;
2. Neoadjuvant chemotherapy before and after surgical resection;
Preoperative neoadjuvant chemotherapy can obviously remit the advancement of tumor. Postoperative adjuvant chemotherapy can consolidate the surgical treatment， thereby extending the survival time and increasing survival rate of patients.
3. Palliative treatment for advanced and metastatic tumors.